254 related articles for article (PubMed ID: 36493559)
21. Ocrelizumab in pediatric multiple sclerosis.
Bibinoğlu Amirov C; Saltık S; Yalçınkaya C; Tütüncü M; Saip S; Siva A; Uygunoğlu U
Eur J Paediatr Neurol; 2023 Mar; 43():1-5. PubMed ID: 36724688
[TBL] [Abstract][Full Text] [Related]
22. Two cases of meningitis associated with ocrelizumab therapy.
Theriault M; Solomon AJ
Mult Scler Relat Disord; 2020 Feb; 38():101866. PubMed ID: 31821962
[TBL] [Abstract][Full Text] [Related]
23. Clinical and Immunological Impact of Ocrelizumab Extended Interval Dosing in Multiple Sclerosis: A Single-Center, Real-World Experience.
Nasello M; Zancan V; Rinaldi V; Marrone A; Reniè R; Diamant S; Marconi M; Le Mura L; Salvetti M; Buscarinu MC; Bellucci G
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791391
[TBL] [Abstract][Full Text] [Related]
24. Ocrelizumab for Treating Patients with Primary Progressive Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Auguste P; Colquitt J; Connock M; Loveman E; Court R; Ciccarelli O; Counsell C; Armoiry X
Pharmacoeconomics; 2020 Jun; 38(6):527-536. PubMed ID: 32048205
[TBL] [Abstract][Full Text] [Related]
25. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies.
Mayer L; Kappos L; Racke MK; Rammohan K; Traboulsee A; Hauser SL; Julian L; Köndgen H; Li C; Napieralski J; Zheng H; Wolinsky JS
Mult Scler Relat Disord; 2019 May; 30():236-243. PubMed ID: 30844611
[TBL] [Abstract][Full Text] [Related]
26. Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis.
Hauser SL; Bar-Or A; Weber MS; Kletzl H; Günther A; Manfrini M; Model F; Mercier F; Petry C; Wing Q; Koendgen H; Smith T; Kappos L
Neurol Neuroimmunol Neuroinflamm; 2023 Mar; 10(2):. PubMed ID: 36792367
[TBL] [Abstract][Full Text] [Related]
27. Real-world evaluation of ocrelizumab in multiple sclerosis: A systematic review.
Montalban X; Matthews PM; Simpson A; Petrie JL; Sammon C; Ramagopalan S; Disanto G; Kuhle J
Ann Clin Transl Neurol; 2023 Mar; 10(3):302-311. PubMed ID: 36728340
[TBL] [Abstract][Full Text] [Related]
28. Shorter infusion time of ocrelizumab: Results from the randomized, double-blind ENSEMBLE PLUS substudy in patients with relapsing-remitting multiple sclerosis.
Hartung HP; Berger T; Bermel RA; Brochet B; Carroll WM; Holmøy T; Karabudak R; Killestein J; Nos C; Patti F; Ross AP; Vanopdenbosch L; Vollmer T; Buffels R; Garas M; Kadner K; Manfrini M; Wang Q; Freedman MS
Mult Scler Relat Disord; 2020 Nov; 46():102492. PubMed ID: 33039944
[TBL] [Abstract][Full Text] [Related]
29. Dengue fever in a multiple sclerosis patient taking Ocrelizumab.
Guerra T; Bollo L; Trojano M; Iaffaldano P
Mult Scler; 2021 Nov; 27(13):2116-2118. PubMed ID: 34449289
[TBL] [Abstract][Full Text] [Related]
30. Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis.
Barkhof F; Kappos L; Wolinsky JS; Li DKB; Bar-Or A; Hartung HP; Belachew S; Han J; Julian L; Sauter A; Napieralski J; Koendgen H; Hauser SL
Neurology; 2019 Nov; 93(19):e1778-e1786. PubMed ID: 31484710
[TBL] [Abstract][Full Text] [Related]
31. Real-world evidence of ocrelizumab-treated relapsing multiple sclerosis cohort shows changes in progression independent of relapse activity mirroring phase 3 trials.
Ingwersen J; Masanneck L; Pawlitzki M; Samadzadeh S; Weise M; Aktas O; Meuth SG; Albrecht P
Sci Rep; 2023 Sep; 13(1):15003. PubMed ID: 37696848
[TBL] [Abstract][Full Text] [Related]
32. Real-world experience of ocrelizumab initiation in a diverse multiple sclerosis population.
Coban H; Germaine S; Dimaandal I; Haberli N; Padam C; Creed MA; Imitola J
Mult Scler Relat Disord; 2021 Aug; 53():103021. PubMed ID: 34077828
[TBL] [Abstract][Full Text] [Related]
33. Ocrelizumab: its efficacy and safety in multiple sclerosis.
Juanatey A; Blanco-Garcia L; Tellez N
Rev Neurol; 2018 Jun; 66(12):423-433. PubMed ID: 29897610
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with suboptimal response to prior disease-modifying therapies: A primary analysis from the phase 3b CASTING single-arm, open-label trial.
Vermersch P; Oreja-Guevara C; Siva A; Van Wijmeersch B; Wiendl H; Wuerfel J; Buffels R; Kadner K; Kuenzel T; Comi G;
Eur J Neurol; 2022 Mar; 29(3):790-801. PubMed ID: 34748672
[TBL] [Abstract][Full Text] [Related]
35. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Hauser SL; Bar-Or A; Comi G; Giovannoni G; Hartung HP; Hemmer B; Lublin F; Montalban X; Rammohan KW; Selmaj K; Traboulsee A; Wolinsky JS; Arnold DL; Klingelschmitt G; Masterman D; Fontoura P; Belachew S; Chin P; Mairon N; Garren H; Kappos L;
N Engl J Med; 2017 Jan; 376(3):221-234. PubMed ID: 28002679
[TBL] [Abstract][Full Text] [Related]
36. Ocrelizumab in Multiple Sclerosis: A Real-World Study From Spain.
Sempere AP; Berenguer-Ruiz L; Borrego-Soriano I; Burgos-San Jose A; Concepcion-Aramendia L; Volar L; Aragones M; Palazón-Bru A
Front Neurol; 2020; 11():592304. PubMed ID: 33519676
[No Abstract] [Full Text] [Related]
37. Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone.
Foo EC; Russell M; Lily O; Ford HL
Mult Scler Relat Disord; 2020 Sep; 44():102330. PubMed ID: 32599468
[TBL] [Abstract][Full Text] [Related]
38. Real-world effectiveness, safety and immunogenicity of ocrelizumab in turkish multiple sclerosis patients: a single-center experience for 4-year follow-up.
Erdogan T; Cansu C; Kocer B; Akkaya S; Kokmen H
Acta Neurol Belg; 2024 May; ():. PubMed ID: 38769274
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis.
Yang H; Duchesneau E; Foster R; Guerin A; Ma E; Thomas NP
J Med Econ; 2017 Oct; 20(10):1056-1065. PubMed ID: 28703659
[TBL] [Abstract][Full Text] [Related]
40. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.
Wolinsky JS; Arnold DL; Brochet B; Hartung HP; Montalban X; Naismith RT; Manfrini M; Overell J; Koendgen H; Sauter A; Bennett I; Hubeaux S; Kappos L; Hauser SL
Lancet Neurol; 2020 Dec; 19(12):998-1009. PubMed ID: 33129442
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
